Interview with Greg Ball
The US FDA has been advocating for aggregate program-level safety evaluations since 1988 when the ISS was introduced (the IND Safety Reporting Final Rule).Aggregate data analysis looks at all available data holistically rather than relying on individual case reports. This allows for a more complete understanding of potential risks associated with a drug or vaccine.In the near future, more companies will adopt a systematic approach to aggregate safety assessment planning and IND safety reporting.This process will develop a better understanding of the safety profile of drugs and ensure that patients' safety is well-thought-of.